Canada Pension Plan Investment Board bought a new position in AtriCure, Inc. (NASDAQ:ATRC – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 14,100 shares of the medical device company’s stock, valued at approximately $395,000.
A number of other institutional investors have also made changes to their positions in ATRC. Smartleaf Asset Management LLC lifted its stake in AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the last quarter. Scotia Capital Inc. increased its stake in AtriCure by 1.2% during the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after purchasing an additional 457 shares during the last quarter. ProShare Advisors LLC increased its stake in AtriCure by 6.6% during the fourth quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock valued at $349,000 after purchasing an additional 543 shares during the last quarter. Captrust Financial Advisors raised its holdings in shares of AtriCure by 7.9% during the fourth quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock worth $314,000 after purchasing an additional 579 shares during the period. Finally, Mackenzie Financial Corp raised its holdings in shares of AtriCure by 5.3% during the fourth quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock worth $545,000 after purchasing an additional 683 shares during the period. 99.11% of the stock is currently owned by institutional investors.
AtriCure Price Performance
Shares of NASDAQ ATRC opened at $52.59 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The firm has a market capitalization of $2.68 billion, a PE ratio of 250.44 and a beta of 1.26. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $52.69. The business’s fifty day moving average price is $39.19 and its two-hundred day moving average price is $32.56.
Analyst Ratings Changes
Several research analysts have recently commented on ATRC shares. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Piper Sandler increased their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. BTIG Research raised their target price on shares of AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, August 24th. Finally, Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, AtriCure has a consensus rating of “Moderate Buy” and an average target price of $52.00.
View Our Latest Analysis on AtriCure
Insider Transactions at AtriCure
In other AtriCure news, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the transaction, the director directly owned 22,809 shares of the company’s stock, valued at $884,989.20. The trade was a 13.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Karl S. Dahlquist sold 9,370 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $48.89, for a total transaction of $458,099.30. Following the transaction, the insider directly owned 87,319 shares of the company’s stock, valued at $4,269,025.91. The trade was a 9.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,616 shares of company stock worth $2,149,994 over the last 90 days. Corporate insiders own 4.00% of the company’s stock.
AtriCure Company Profile
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Read More
- Five stocks we like better than AtriCure
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Free Report).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
